4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly EBITDA Margin came in at 2416.15% in Q1 2026, up 38059100.0% year-on-year from N/an in Q1 2025, and down 14071.45% on a QoQ basis from 17.29% in Q4 2025.
4D Molecular Therapeutics (FDMT) EBITDA Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of EBITDA Margin data on file, last reported at 2416.15% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 38059100.0% year-over-year to 2416.15% in Q1 2026; TTM through Mar 2026 was 203.47%, a 88382262.0% increase from a year earlier, with the FY2025 full-year figure at 187.24%, up 50749114.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 2416.15%, down from 17.29% in the prior quarter.
- Over the last five years, EBITDA Margin for FDMT reached as high as 192905.26% in Q4 2023 and fell as low as 5611700.0% in Q4 2024.
- Historically, EBITDA Margin has averaged 529953.49% across 5 years, with a median of 13446.03% in 2023.
- Across the five-year window, EBITDA Margin sank 580460526 bps in 2024 and jumped 561171729 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 2303.13% in 2022, then jumped by 8476 bps to 192905.26% in 2023, then slumped by 3009 bps to 5611700.0% in 2024, then surged by 100 bps to 17.29% in 2025, then plunged by 14071 bps to 2416.15% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 2416.15% in Q1 2026, 17.29% in Q4 2025, and 67983.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -2,416.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,416.15% |
| Dec 31, 2025 | 17.29% |
| Sep 30, 2025 | -67,983.33% |
| Jun 30, 2025 | -396,373.33% |
| Mar 31, 2025 | -383,007.14% |
| Dec 31, 2024 | -5,611,700.00% |
| Sep 30, 2024 | -1,704,400.00% |
| Jun 30, 2024 | -849,120.00% |
| Mar 31, 2024 | -136,200.00% |
| Dec 31, 2023 | 192,905.26% |
| Sep 30, 2023 | -69.16% |
| Jun 30, 2023 | -13,446.03% |
| Mar 31, 2023 | -10,102.68% |
| Dec 31, 2022 | -2,303.13% |
| Sep 30, 2022 | -5,299.00% |
| Jun 30, 2022 | -17,546.91% |
| Mar 31, 2022 | -2,165.05% |
| Dec 31, 2021 | -26,917.39% |
| Sep 30, 2021 | -1,658.93% |
| Jun 30, 2021 | -52.10% |